No association between anti-myelin oligodendrocyte glycoprotein antibodies and serum/cerebrospinal fluid levels of the soluble interleukin-6 receptor complex in multiple sclerosis

Neuroscience Letters

Volumn 305, Issue 1, 2001, Pages 13-16

  Padberg, Frank ^a   Haase, Claus G ^b   Feneberg, Wolfgang ^c   Schwarz, Markus J ^a   Hampel, Harald ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b MAX PLANCK INSTITUTE OF NEUROBIOLOGY   (Germany)

^c Marianne Strauss Clinic   (Germany)

Author keywords

Cerebrospinal fluid; Interleukin 6; Myelin oligodendrocyte glycoprotein; Serum; Soluble glycoprotein 130; Soluble interleukin 6 receptor

Indexed keywords

ANTIBODY; INTERLEUKIN 6 RECEPTOR; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; INTERLEUKIN 6; PROTEIN ANTIBODY;

ADULT; ANTIBODY DETECTION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEMYELINATION; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; RECEPTOR UPREGULATION; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; DISEASE ASSOCIATION;

ADULT; BLOOD; CEREBROSPINAL FLUID; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MYELIN-ASSOCIATED GLYCOPROTEIN; RECEPTORS, INTERLEUKIN-6; REFERENCE VALUES; SOLUBILITY;

EID: 0035827430     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(01)01792-X     Document Type: Article

References (20)

1. Eugster H.P., Frei K., Kopf M., Lassmann H., Fontana A. IL-6-deficient mice resist myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. Eur. J. Immunol. 28:1998;2178-2187.
2. Frei K., Fredrikson S., Fontana A., Link H. Interleukin-6 is elevated in plasma in multiple sclerosis. J. Neuroimmunol. 31:1991;147-153.
3. Genain C.P., Cannella B., Hauser S.L., Raine C.S. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nature Med. 5:1999;170-175.
4. Hohlfeld R. Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives. Brain. 120:1997;865-916.
5. Karmi A., Bakimer-Kleiner R., Abramsky O., Ben-Nun A. Elevated levels of antibody to myelin oligodendrocyte glycoprotein is not specific for patients with multiple sclerosis. Arch. Neurol. 56:1999;311-315.
6. Lindert R.B., Haase C.G., Brehm U., Linington C., Wekerle H., Hohlfeld R. Multiple sclerosis: B- and T-cell responses to the extracellular domain of the myelin oligodendrocyte glycoprotein. Brain. 122:1999;2089-2099.
7. Lublin F.D., Reingold S.C. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology. 46:1996;907-911.
8. Mendel I., Katz A., Kozak N., Ben-Nun A., Revel M. Interleukin-6 functions in autoimmune encephalomyelitis: a study in gene-targeted mice. Eur. J. Immunol. 28:1998;1727-1737.
9. Navikas V., Link H. Review: Cytokines and the pathogenesis of multiple sclerosis. J. Neurosci. Res. 45:1996;322-333.
10. Nukina H., Sudo N., Komaki G., Yu X., Mine K., Kubo C., Okuda Y. The restraint stress-induced elevation in plasma interleukin-6 negatively regulates the plasma TNF-alpha level. Neuroimmunomodulation. 5:1998;323-327.
11. Okuda Y., Sakoda S., Bernard C.C.A., Fujimura H., Saeki Y., Kishimoto T., Yanagihara T. IL-6-deficient mice are resistant to the induction of experimental autoimmune encephalomyelitis provoked by myelin oligodendrocyte glycoprotein. Int. Immunol. 10:1998;703-708.
12. Okuda Y., Sakoda S., Fujimura H., Saeki Y., Kishimoto T., Yanagihara T. IL-6 plays a crucial role in the induction phase of myelin oligodendrocyte glycoprotein 35-55 induced experimental autoimmune encephalomyelitis. J. Neuroimmunol. 101:1999;188-196.
13. Padberg F., Feneberg W., Schmidt S., Schwarz M.J., Körschenhausen D., Greenberg B.D., Nolde T., Müller N., Trapmann H., König N., Möller H.J., Hampel H. CSF and serum levels of soluble interleukin-6 receptors (sIL-6R and sgp130), but not of interleukin-6 are altered in multiple sclerosis. J. Neuroimmunol. 99:1999;218-223.
14. Poser C.M., Paty D.W., Scheinberg L., McDonald W.I., Davis F.A., Ebers G.C., Johnson K.P., Sibley W.A., Silberberg D.H., Tourtellotte W.W. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 13:1983;227-231.
15. Raine C.S., Cannella B., Hauser S.L., Genain C.P. Demyelination in primate autoimmune encephalomyelitis and acute multiple sclerosis lesions: a case for antigen-specific antibody mediation. Ann. Neurol. 46:1999;144-160.
16. Reindl M., Linington C., Brehm U., Egg R., Dilitz E., Deisenhammer F., Poewe W., Berger T. Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study. Brain. 122:1999;2047-2056.
17. Samoilova E.B., Horton J.L., Hilliard B., Liu T.S.T., Chen Y. IL-6-deficient mice are resistant to experimental autoimmune encephalomyelitis: Roles of IL-6 in the activation and differentiation of autoreactive T cells. J. Immunol. 161:1998;6480-6486.
18. Schmidt S., Papassotiropoulos A., Bagli M., Harzheim M., Heun R., Klockgether T. No association of serum levels of interleukin-6 nd ist soluble receptor components with a genetic variation in the 3′flanking region of the interleukin-6 gene in patients with multiple sclerosis. Neurosci. Lett. 294:2000;139-142.
19. Schönrock L.M., Gawlowski G., Brück W. Interleukin-6 expression in human multiple sclerosis lesions. Neurosci. Lett. 294:2000;45-48.
20. Thavasu P.W., Longhurst S., Joel S.P., Slevin M.L., Balkwill F.R. Measuring cytokine levels in blood. Importance of anticoagulants, processing, and storage conditions. J. Immunol. Methods. 153:1992;115-124.